Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    5-Methoxy-2-Aminoindane

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Clearmind Files Patent for Non-Hallucinogenic Psychedelic Drug
    Clearmind Files Patent for Non-Hallucinogenic Psychedelic Drug

    17 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/17/3189045/0/en/Clearmind-Medicine-Files-Israeli-Patent-for-Novel-Non-Hallucinogenic-Neuroplastogen-Treatment-for-Depression.html

    GLOBENEWSWIRE
    17 Nov 2025
    Share Share
    Clearmind Files US Patent for Non-Hallucinogenic MEAI Therapy
    Clearmind Files US Patent for Non-Hallucinogenic MEAI Therapy

    31 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/31/3178255/0/en/Clearmind-Medicine-Advances-Fight-Against-Cocaine-Addiction-with-Publication-of-U-S-Patent-Application-for-Its-Non-Hallucinogenic-Neuroplastogen-MEAI-Therapy.html

    GLOBENEWSWIRE
    31 Oct 2025
    Share Share
    Scisparc & Clearmind Collaborate On US Patent For Binge Behavior
    Scisparc & Clearmind Collaborate On US Patent For Binge Behavior

    20 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/20/3169272/0/en/SciSparc-Clearmind-Collaboration-Leads-to-Publication-of-U-S-Patent-Application-Targeting-Binge-Behavior-Disorders.html

    GLOBENEWSWIRE
    20 Oct 2025
    Share Share
    SciSparc-Clearmind Win EU Patent for Cocaine Therapy
    SciSparc-Clearmind Win EU Patent for Cocaine Therapy

    12 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/12/3079029/0/en/SciSparc-Clearmind-Collaboration-Leads-to-Publication-of-European-Patent-for-Psychedelic-Based-Combination-Therapy-for-Cocaine-Addiction.html

    GLOBENEWSWIRE
    12 May 2025
    Share Share
    Clearmind Medicine Gets FDA IND Approval For Alcoholism Treatment Trial
    Clearmind Medicine Gets FDA IND Approval For Alcoholism Treatment Trial

    16 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/16/2913847/0/en/Clearmind-Medicine-Obtains-IND-Approval-from-the-FDA-to-Start-the-Phase-I-IIa-Clinical-Trial-with-its-Innovative-Treatment-for-Alcoholism.html

    GLOBENEWSWIRE
    16 Jul 2024
    Share Share
    Clearmind Medicine Files US Patent For Metabolic Syndrome Treatment
    Clearmind Medicine Files US Patent For Metabolic Syndrome Treatment

    16 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/16/2913567/0/en/Clearmind-Medicine-Announces-Submission-of-US-Patent-Application-for-Treating-Metabolic-Syndrome-and-Weight-loss.html

    GLOBENEWSWIRE
    16 Jul 2024
    Share Share